Nervapax

Nervapax operates at the intersection of medical devices, neuroscience, wearables, and therapeutics. Its focus is unusually specific: a wearable device intended to prevent cluster headache attacks through non-invasive nerve stimulation, with the stated aim of avoiding pharmaceutical treatment. The company’s differentiating claims are its condition-specific focus, a wearable form factor, and a patient-centered development approach informed by people affected by cluster headache as well as clinicians and relatives. Its participation in the Danish Tech Challenge provides a hardware-startup development milestone, while more than DKK 1.2 million in soft funding indicates early support rather than a disclosed institutional financing round. With a 2023 founding date and a team-size bracket of 1–10 employees, Nervapax appears to be an early-stage developer.

Nervapax’s trajectory is that of an early-stage medical-device developer rather than a company with documented commercial scale. Founded in 2023, it is developing a wearable device that uses non-invasive neuromodulation to try to prevent cluster headache attacks. The company reports more than DKK 1.2 million in soft funding, equivalent to approximately €160,000, and participation in the Danish Tech Challenge. The stated employee range is 1–10, and there is no specific hiring news or evidence of recent layoffs. Nervapax also says its work draws on patient and clinician conversations, alongside expertise in neuroscience, physiotherapy, clinical medicine, regulation, and usability. Without dated product releases or hiring milestones, the available evidence does not support a more granular account of acceleration or slowdown.